TY - JOUR AU - Ferlay, J. AU - Soerjomataram, I. AU - Dikshit, R. AU - Eser, S. AU - Mathers, C. AU - Rebelo, M. PY - 2015 DA - 2015// TI - Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 JO - Int J Cancer VL - 136 UR - https://doi.org/10.1002/ijc.29210 DO - 10.1002/ijc.29210 ID - Ferlay2015 ER - TY - JOUR AU - Clarke, R. AU - Tyson, J. J. AU - Dixon, J. M. PY - 2015 DA - 2015// TI - Endocrine resistance in breast cancer—an overview and update JO - Mol Cell Endocrinol VL - 418 UR - https://doi.org/10.1016/j.mce.2015.09.035 DO - 10.1016/j.mce.2015.09.035 ID - Clarke2015 ER - TY - JOUR AU - Reis-Filho, J. S. AU - Pusztai, L. PY - 2011 DA - 2011// TI - Gene expression profiling in breast cancer: classification, prognostication, and prediction JO - Lancet VL - 378 UR - https://doi.org/10.1016/S0140-6736(11)61539-0 DO - 10.1016/S0140-6736(11)61539-0 ID - Reis-Filho2011 ER - TY - JOUR AU - Miller, W. R. AU - Larionov, A. AU - Renshaw, L. AU - Anderson, T. J. AU - Walker, J. R. AU - Krause, A. PY - 2009 DA - 2009// TI - Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.16.8849 DO - 10.1200/JCO.2008.16.8849 ID - Miller2009 ER - TY - JOUR AU - Colleoni, M. AU - Montagna, E. PY - 2012 DA - 2012// TI - Neoadjuvant therapy for ER-positive breast cancers JO - Ann Oncol. VL - 23 UR - https://doi.org/10.1093/annonc/mds305 DO - 10.1093/annonc/mds305 ID - Colleoni2012 ER - TY - JOUR AU - Ma, C. X. AU - Sanchez, C. G. AU - Ellis, M. J. PY - 2009 DA - 2009// TI - Predicting endocrine therapy responsiveness in breast cancer JO - Oncology VL - 23 ID - Ma2009 ER - TY - JOUR PY - 2005 DA - 2005// TI - Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials JO - Lancet. VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)66544-0 DO - 10.1016/S0140-6736(05)66544-0 ID - ref7 ER - TY - JOUR AU - DeMichele, A. AU - Yee, D. AU - Berry, D. A. AU - Albain, K. S. AU - Benz, C. C. AU - Boughey, J. PY - 2015 DA - 2015// TI - The neoadjuvant model is still the future for drug development in breast cancer JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-1760 DO - 10.1158/1078-0432.CCR-14-1760 ID - DeMichele2015 ER - TY - JOUR AU - Bardia, A. AU - Baselga, J. PY - 2013 DA - 2013// TI - Neoadjuvant therapy as a platform for drug development and approval in breast cancer JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0916 DO - 10.1158/1078-0432.CCR-13-0916 ID - Bardia2013 ER - TY - JOUR AU - Robertson, J. F. R. AU - Llombart-Cussac, A. AU - Rolski, J. AU - Feltl, D. AU - Dewar, J. AU - Macpherson, E. PY - 2009 DA - 2009// TI - Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.1136 DO - 10.1200/JCO.2008.21.1136 ID - Robertson2009 ER - TY - JOUR AU - Ellis, M. J. AU - Llombart-Cussac, A. AU - Feltl, D. AU - Dewar, J. A. AU - Jasiowka, M. AU - Hewson, N. PY - 2015 DA - 2015// TI - Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.61.5831 DO - 10.1200/JCO.2015.61.5831 ID - Ellis2015 ER - TY - JOUR AU - Ziauddin, M. F. AU - Hua, D. AU - Tang, S. C. PY - 2014 DA - 2014// TI - Emerging strategies to overcome resistance to endocrine therapy for breast cancer JO - Cancer Metastasis Rev VL - 33 UR - https://doi.org/10.1007/s10555-014-9504-6 DO - 10.1007/s10555-014-9504-6 ID - Ziauddin2014 ER - TY - JOUR AU - Mehta, R. S. AU - Barlow, W. E. AU - Albain, K. S. AU - Vandenberg, T. A. AU - Dakhil, S. R. AU - Tirumali, N. R. PY - 2012 DA - 2012// TI - Combination anastrozole and fulvestrant in metastatic breast cancer JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1201622 DO - 10.1056/NEJMoa1201622 ID - Mehta2012 ER - TY - JOUR AU - Bergh, J. AU - Jonsson, P. E. AU - Lidbrink, E. K. AU - Trudeau, M. AU - Eiermann, W. AU - Brattstrom, D. PY - 2012 DA - 2012// TI - FACT: An open-label randomized phase iii study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.1095 DO - 10.1200/JCO.2011.38.1095 ID - Bergh2012 ER - TY - JOUR AU - Dees, E. C. AU - Carey, L. A. PY - 2013 DA - 2013// TI - Improving endocrine therapy for breast cancer: it's not that simple JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.46.2655 DO - 10.1200/JCO.2012.46.2655 ID - Dees2013 ER - TY - JOUR AU - Carlson, R. W. AU - O'Neill, A. AU - Vidaurre, T. AU - Gomez, H. L. AU - Badve, S. S. AU - Sledge, G. W. PY - 2012 DA - 2012// TI - A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer JO - Breast Cancer Res Treat VL - 133 UR - https://doi.org/10.1007/s10549-012-1997-5 DO - 10.1007/s10549-012-1997-5 ID - Carlson2012 ER - TY - JOUR AU - Martin, M. AU - Loibl, S. AU - Minckwitz, G. AU - Morales, S. AU - Martinez, N. AU - Guerrero, A. PY - 2015 DA - 2015// TI - Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.57.2388 DO - 10.1200/JCO.2014.57.2388 ID - Martin2015 ER - TY - JOUR AU - Arthur, L. M. AU - Turnbull, A. K. AU - Renshaw, L. AU - Keys, J. AU - Thomas, J. S. AU - Wilson, T. R. PY - 2014 DA - 2014// TI - Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer JO - Breast Cancer Res Treat VL - 147 UR - https://doi.org/10.1007/s10549-014-3080-x DO - 10.1007/s10549-014-3080-x ID - Arthur2014 ER - TY - JOUR AU - Baselga, J. AU - Semiglazov, V. AU - Dam, P. AU - Manikhas, A. AU - Bellet, M. AU - Mayordomo, J. PY - 2009 DA - 2009// TI - Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.18.8391 DO - 10.1200/JCO.2008.18.8391 ID - Baselga2009 ER - TY - JOUR AU - Dukelow, T. AU - Kishan, D. AU - Khasraw, M. AU - Murphy, C. G. PY - 2015 DA - 2015// TI - CDK4/6 inhibitors in breast cancer JO - Anticancer Drugs VL - 26 UR - https://doi.org/10.1097/CAD.0000000000000249 DO - 10.1097/CAD.0000000000000249 ID - Dukelow2015 ER - TY - JOUR AU - Finn, R. S. AU - Crown, J. P. AU - Lang, I. AU - Boer, K. AU - Bondarenko, I. M. AU - Kulyk, S. O. PY - 2015 DA - 2015// TI - The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71159-3 DO - 10.1016/S1470-2045(14)71159-3 ID - Finn2015 ER - TY - JOUR AU - Turner, N. C. AU - Huang Bartlett, C. AU - Cristofanilli, M. PY - 2015 DA - 2015// TI - Palbociclib in hormone-receptor-positive advanced breast cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMc1510345 DO - 10.1056/NEJMc1510345 ID - Turner2015 ER - TY - JOUR AU - Treppendahl, M. B. AU - Kristensen, L. S. AU - Gronbaek, K. PY - 2014 DA - 2014// TI - Predicting response to epigenetic therapy JO - J Clin Invest VL - 124 UR - https://doi.org/10.1172/JCI69737 DO - 10.1172/JCI69737 ID - Treppendahl2014 ER - TY - JOUR AU - Camacho, L. AU - Dasgupta, A. AU - Jiralerspong, S. PY - 2015 DA - 2015// TI - Metformin in breast cancer—an evolving mystery JO - Breast Cancer Res. VL - 17 UR - https://doi.org/10.1186/s13058-015-0598-8 DO - 10.1186/s13058-015-0598-8 ID - Camacho2015 ER - TY - JOUR AU - Kim, J. AU - Lim, W. AU - Kim, E. K. AU - Kim, M. K. AU - Paik, N. S. AU - Jeong, S. S. PY - 2014 DA - 2014// TI - Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR) JO - BMC Cancer. VL - 14 UR - https://doi.org/10.1186/1471-2407-14-170 DO - 10.1186/1471-2407-14-170 ID - Kim2014 ER - TY - JOUR AU - Dowling, R. J. O. AU - Niraula, S. AU - Chang, M. C. AU - Done, S. J. AU - Ennis, M. AU - McCready, D. R. PY - 2015 DA - 2015// TI - Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study JO - Breast Cancer Res. VL - 17 UR - https://doi.org/10.1186/s13058-015-0540-0 DO - 10.1186/s13058-015-0540-0 ID - Dowling2015 ER - TY - JOUR AU - Nguyen, V. T. AU - Barozzi, I. AU - Faronato, M. AU - Lombardo, Y. AU - Steel, J. H. AU - Patel, N. PY - 2015 DA - 2015// TI - Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion JO - Nat Commun. VL - 6 UR - https://doi.org/10.1038/ncomms10044 DO - 10.1038/ncomms10044 ID - Nguyen2015 ER - TY - JOUR AU - Higgins, M. J. AU - Prowell, T. M. AU - Blackford, A. L. AU - Byrne, C. AU - Khouri, N. F. AU - Slater, S. A. PY - 2012 DA - 2012// TI - A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer JO - Breast Cancer Res Treat VL - 131 UR - https://doi.org/10.1007/s10549-011-1858-7 DO - 10.1007/s10549-011-1858-7 ID - Higgins2012 ER - TY - JOUR AU - Ottewell, P. D. AU - Wang, N. AU - Brown, H. K. AU - Reeves, K. J. AU - Fowles, C. A. AU - Croucher, P. I. PY - 2014 DA - 2014// TI - Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-1246 DO - 10.1158/1078-0432.CCR-13-1246 ID - Ottewell2014 ER - TY - JOUR AU - Coleman, R. AU - Powles, T. AU - Paterson, A. AU - Gnant, M. AU - Anderson, S. AU - Diel, I. PY - 2015 DA - 2015// TI - Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials JO - Lancet VL - 386 UR - https://doi.org/10.1016/S0140-6736(15)60908-4 DO - 10.1016/S0140-6736(15)60908-4 ID - Coleman2015 ER - TY - JOUR AU - Lipton, A. AU - Chapman, J. A. W. AU - Demers, L. AU - Shepherd, L. E. AU - Han, L. AU - Wilson, C. F. PY - 2011 DA - 2011// TI - Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.31.5069 DO - 10.1200/JCO.2010.31.5069 ID - Lipton2011 ER - TY - JOUR AU - Kim, C. AU - Tang, G. AU - Pogue-Geile, K. L. AU - Costantino, J. P. AU - Baehner, F. L. AU - Baker, J. PY - 2011 DA - 2011// TI - Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.32.9615 DO - 10.1200/JCO.2010.32.9615 ID - Kim2011 ER - TY - JOUR AU - Anderson, H. AU - Hills, M. AU - Zabaglo, L. AU - A'Hern, R. AU - Leary, A. F. AU - Haynes, B. P. PY - 2011 DA - 2011// TI - Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdq700 DO - 10.1093/annonc/mdq700 ID - Anderson2011 ER - TY - JOUR AU - Dowsett, M. AU - Allred, C. AU - Knox, J. AU - Quinn, E. AU - Salter, J. AU - Wale, C. PY - 2008 DA - 2008// TI - Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.12.9437 DO - 10.1200/JCO.2007.12.9437 ID - Dowsett2008 ER - TY - JOUR AU - Mohammed, H. AU - Russell, I. A. AU - Stark, R. AU - Rueda, O. M. AU - Hickey, T. E. AU - Tarulli, G. A. PY - 2015 DA - 2015// TI - Progesterone receptor modulates ER alpha action in breast cancer JO - Nature VL - 523 UR - https://doi.org/10.1038/nature14583 DO - 10.1038/nature14583 ID - Mohammed2015 ER - TY - JOUR AU - Gianni, L. AU - Pienkowski, T. AU - Im, Y. H. AU - Roman, L. AU - Tseng, L. M. AU - Liu, M. C. PY - 2012 DA - 2012// TI - Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70336-9 DO - 10.1016/S1470-2045(11)70336-9 ID - Gianni2012 ER - TY - JOUR AU - Costello, J. C. AU - Heiser, L. M. AU - Georgii, E. AU - Gonen, M. AU - Menden, M. P. AU - Wang, N. J. PY - 2014 DA - 2014// TI - A community effort to assess and improve drug sensitivity prediction algorithms JO - Nat Biotechnol VL - 32 UR - https://doi.org/10.1038/nbt.2877 DO - 10.1038/nbt.2877 ID - Costello2014 ER - TY - JOUR AU - Perou, C. M. AU - Sorlie, T. AU - Eisen, M. B. AU - Rijn, M. AU - Jeffrey, S. S. AU - Rees, C. A. PY - 2000 DA - 2000// TI - Molecular portraits of human breast tumours JO - Nature VL - 406 UR - https://doi.org/10.1038/35021093 DO - 10.1038/35021093 ID - Perou2000 ER - TY - JOUR AU - Parker, J. S. AU - Mullins, M. AU - Cheang, M. C. AU - Leung, S. AU - Voduc, D. AU - Vickery, T. PY - 2009 DA - 2009// TI - Supervised risk predictor of breast cancer based on intrinsic subtypes JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.18.1370 DO - 10.1200/JCO.2008.18.1370 ID - Parker2009 ER - TY - JOUR AU - Sparano, J. A. AU - Gray, R. J. AU - Makower, D. F. AU - Pritchard, K. I. AU - Albain, K. S. AU - Hayes, D. F. PY - 2015 DA - 2015// TI - Prospective validation of a 21-gene expression assay in breast cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510764 DO - 10.1056/NEJMoa1510764 ID - Sparano2015 ER - TY - JOUR AU - Sims, A. H. AU - Smethurst, G. J. AU - Hey, Y. AU - Okoniewski, M. J. AU - Pepper, S. D. AU - Howell, A. PY - 2008 DA - 2008// TI - The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets—improving meta-analysis and prediction of prognosis JO - BMC Med Genomics. VL - 1 UR - https://doi.org/10.1186/1755-8794-1-42 DO - 10.1186/1755-8794-1-42 ID - Sims2008 ER - TY - JOUR AU - Cleator, S. J. AU - Powles, T. J. AU - Dexter, T. AU - Fulford, L. AU - Mackay, A. AU - Smith, I. E. PY - 2006 DA - 2006// TI - The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis JO - Breast Cancer Res VL - 8 UR - https://doi.org/10.1186/bcr1506 DO - 10.1186/bcr1506 ID - Cleator2006 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Sims, A. H. AU - Bartlett, J. M. S. PY - 2008 DA - 2008// TI - Approaches towards expression profiling the response to treatment JO - Breast Cancer Res VL - 10 UR - https://doi.org/10.1186/bcr2196 DO - 10.1186/bcr2196 ID - Sims2008 ER - TY - JOUR AU - Cortazar, P. AU - Zhang, L. AU - Untch, M. AU - Mehta, K. AU - Costantino, J. P. AU - Wolmark, N. PY - 2014 DA - 2014// TI - Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(13)62422-8 DO - 10.1016/S0140-6736(13)62422-8 ID - Cortazar2014 ER - TY - JOUR AU - Nik-Zainal, S. AU - Loo, P. AU - Wedge, D. C. AU - Alexandrov, L. B. AU - Greenman, C. D. AU - Lau, K. W. PY - 2012 DA - 2012// TI - The life history of 21 breast cancers JO - Cell VL - 149 UR - https://doi.org/10.1016/j.cell.2012.04.023 DO - 10.1016/j.cell.2012.04.023 ID - Nik-Zainal2012 ER - TY - JOUR AU - Marous, M. AU - Bieche, I. AU - Paoletti, X. AU - Alt, M. AU - Razak, A. R. AU - Stathis, A. PY - 2015 DA - 2015// TI - Designs of preoperative biomarkers trials in oncology: a systematic review of the literature JO - Ann Oncol VL - 26 ID - Marous2015 ER - TY - JOUR AU - Smith, I. E. AU - Johnson, L. AU - Dowsett, M. AU - Robertson, J. F. R. AU - Robison, L. E. AU - Kokan, J. S. PY - 2011 DA - 2011// TI - Trial of perioperative endocrine therapy: individualizing care (POETIC) JO - J Clin Oncol. VL - 29 ID - Smith2011 ER - TY - JOUR AU - Dowsett, M. AU - Smith, I. E. AU - Ebbs, S. R. AU - Dixon, J. M. AU - Skene, A. AU - Griffith, C. PY - 2005 DA - 2005// TI - Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival JO - Clin Cancer Res VL - 11 ID - Dowsett2005 ER - TY - JOUR AU - Polley, M. Y. C. AU - Leung, S. C. Y. AU - McShane, L. M. AU - Gao, D. X. AU - Hugh, J. C. AU - Mastropasqua, M. G. PY - 2013 DA - 2013// TI - An international Ki67 reproducibility study JO - J Natl Cancer Inst VL - 105 UR - https://doi.org/10.1093/jnci/djt306 DO - 10.1093/jnci/djt306 ID - Polley2013 ER - TY - JOUR AU - Nielsen, T. O. AU - Polley, M. Y. C. PY - 2013 DA - 2013// TI - An international Ki67 reproducibility study: harmonizing scoring methodology JO - Cancer Res. VL - 73 UR - https://doi.org/10.1158/0008-5472.SABCS13-S2-07 DO - 10.1158/0008-5472.SABCS13-S2-07 ID - Nielsen2013 ER - TY - JOUR AU - Turnbull, A. K. AU - Arthur, L. M. AU - Renshaw, L. AU - Larionov, A. A. AU - Kay, C. AU - Dunbier, A. K. PY - 2015 DA - 2015// TI - Accurate prediction and validation of response to endocrine therapy in breast cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.57.8963 DO - 10.1200/JCO.2014.57.8963 ID - Turnbull2015 ER - TY - JOUR AU - Arthur, L. M. AU - Turnbull, A. K. AU - Webber, V. L. AU - Larionov, A. A. AU - Renshaw, L. AU - Kay, C. PY - 2014 DA - 2014// TI - Molecular changes in lobular breast cancers in response to endocrine therapy JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-14-0620 DO - 10.1158/0008-5472.CAN-14-0620 ID - Arthur2014 ER - TY - STD TI - Ma CX, Gao F, Northfelt D, Goetz M, Forero A, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Hoog J, Han J, Guo Z, Vij K, Mardis E, Al-Kateb H, Sanati S, Ellis MJ. A phase II trial of neoadjuvant palbociclib, a cyclindependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+ HER2–) breast cancer (BC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr S6-05. ID - ref54 ER - TY - JOUR AU - Patani, N. AU - Dunbier, A. K. AU - Anderson, H. AU - Ghazoui, Z. AU - Ribas, R. AU - Anderson, E. PY - 2014 DA - 2014// TI - Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-1378 DO - 10.1158/1078-0432.CCR-13-1378 ID - Patani2014 ER - TY - JOUR AU - Ng, C. K. Y. AU - Schultheis, A. M. AU - Bidard, F. C. AU - Weigelt, B. AU - Reis-Filho, J. S. PY - 2015 DA - 2015// TI - Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights JO - JNCI J Natl Cancer Institute. VL - 107 UR - https://doi.org/10.1093/jnci/djv015 DO - 10.1093/jnci/djv015 ID - Ng2015 ER - TY - JOUR AU - Jeselsohn, R. AU - Yelensky, R. AU - Buchwalter, G. AU - Frampton, G. AU - Meric-Bernstam, F. AU - Gonzalez-Angulo, A. M. PY - 2014 DA - 2014// TI - Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2332 DO - 10.1158/1078-0432.CCR-13-2332 ID - Jeselsohn2014 ER - TY - JOUR AU - Segal, C. V. AU - Dowsett, M. PY - 2014 DA - 2014// TI - Estrogen receptor mutations in breast cancer—new focus on an old target JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-14-0067 DO - 10.1158/1078-0432.CCR-14-0067 ID - Segal2014 ER - TY - JOUR AU - Bidard, F. C. AU - Peeters, D. J. AU - Fehm, T. AU - Nole, F. AU - Gisbert-Criado, R. AU - Mavroudis, D. PY - 2014 DA - 2014// TI - Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70069-5 DO - 10.1016/S1470-2045(14)70069-5 ID - Bidard2014 ER - TY - JOUR AU - Bhat-Nakshatri, P. AU - Wang, G. H. AU - Collins, N. R. AU - Thomson, M. J. AU - Geistlinger, T. R. AU - Carroll, J. S. PY - 2009 DA - 2009// TI - Estradiol-regulated microRNAs control estradiol response in breast cancer cells JO - Nucleic Acids Res VL - 37 UR - https://doi.org/10.1093/nar/gkp500 DO - 10.1093/nar/gkp500 ID - Bhat-Nakshatri2009 ER - TY - JOUR AU - Polzer, B. AU - Medoro, G. AU - Pasch, S. AU - Fontana, F. AU - Zorzino, L. AU - Pestka, A. PY - 2014 DA - 2014// TI - Molecular profiling of single circulating tumor cells with diagnostic intention JO - EMBO Mol Med VL - 6 UR - https://doi.org/10.15252/emmm.201404033 DO - 10.15252/emmm.201404033 ID - Polzer2014 ER - TY - JOUR AU - Taube, J. H. AU - Herschkowitz, J. I. AU - Komurov, K. AU - Zhou, A. Y. AU - Gupta, S. AU - Yang, J. PY - 2010 DA - 2010// TI - Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes JO - Proc Natl Acad Sci U S A VL - 107 ID - Taube2010 ER - TY - JOUR AU - Yu, M. AU - Bardia, A. AU - Wittner, B. S. AU - Stott, S. L. AU - Smas, M. E. AU - Ting, D. T. PY - 2013 DA - 2013// TI - Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition JO - Science VL - 339 UR - https://doi.org/10.1126/science.1228522 DO - 10.1126/science.1228522 ID - Yu2013 ER - TY - JOUR AU - Bulfoni, M. AU - Gerratana, L. AU - Ben, F. AU - Marzinotto, S. AU - Sorrentino, M. AU - Turetta, M. PY - 2016 DA - 2016// TI - In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis JO - Breast Cancer Res VL - 18 UR - https://doi.org/10.1186/s13058-016-0687-3 DO - 10.1186/s13058-016-0687-3 ID - Bulfoni2016 ER - TY - JOUR AU - Pestrin, M. AU - Salvianti, F. AU - Galardi, F. AU - Luca, F. AU - Turner, N. AU - Malorni, L. PY - 2015 DA - 2015// TI - Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients JO - Mol Oncol VL - 9 UR - https://doi.org/10.1016/j.molonc.2014.12.001 DO - 10.1016/j.molonc.2014.12.001 ID - Pestrin2015 ER - TY - JOUR AU - Dawson, S. J. AU - Tsui, D. W. Y. AU - Murtaza, M. AU - Biggs, H. AU - Rueda, O. M. AU - Chin, S. F. PY - 2013 DA - 2013// TI - Analysis of circulating tumor DNA to monitor metastatic breast cancer JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1213261 DO - 10.1056/NEJMoa1213261 ID - Dawson2013 ER - TY - JOUR AU - Bettegowda, C. AU - Sausen, M. AU - Leary, R. J. AU - Kinde, I. AU - Wang, Y. X. AU - Agrawal, N. PY - 2014 DA - 2014// TI - Detection of circulating tumor DNA in early- and late-stage human malignancies JO - Sci Transl Med. VL - 6 UR - https://doi.org/10.1126/scitranslmed.3007094 DO - 10.1126/scitranslmed.3007094 ID - Bettegowda2014 ER - TY - JOUR AU - Garcia-Murillas, I. AU - Schiavon, G. AU - Weigelt, B. AU - Ng, C. AU - Hrebien, S. AU - Cutts, R. J. PY - 2015 DA - 2015// TI - Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer JO - Sci Transl Med VL - 7 UR - https://doi.org/10.1126/scitranslmed.aab0021 DO - 10.1126/scitranslmed.aab0021 ID - Garcia-Murillas2015 ER - TY - JOUR AU - Guttery, D. S. AU - Page, K. AU - Hills, A. AU - Woodley, L. AU - Marchese, S. D. AU - Rghebi, B. PY - 2015 DA - 2015// TI - Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer JO - Clin Chem VL - 61 UR - https://doi.org/10.1373/clinchem.2015.238717 DO - 10.1373/clinchem.2015.238717 ID - Guttery2015 ER - TY - JOUR AU - Schiavon, G. AU - Hrebien, S. AU - Garcia-Murillas, I. AU - Cutts, R. J. AU - Pearson, A. AU - Tarazona, N. PY - 2015 DA - 2015// TI - Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer JO - Sci Transl Med. VL - 7 UR - https://doi.org/10.1126/scitranslmed.aac7551 DO - 10.1126/scitranslmed.aac7551 ID - Schiavon2015 ER - TY - JOUR AU - Chandarlapaty, S. AU - Chen, D. AU - He, W. AU - Sung, P. AU - Samoila, A. AU - You, D. PY - 2016 DA - 2016// TI - Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2016.1279 DO - 10.1001/jamaoncol.2016.1279 ID - Chandarlapaty2016 ER - TY - JOUR AU - Fribbens, C. AU - O'Leary, B. AU - Kilburn, L. AU - Hrebien, S. AU - Garcia-Murillas, I. AU - Beaney, M. PY - 2016 DA - 2016// TI - Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.3061 DO - 10.1200/JCO.2016.67.3061 ID - Fribbens2016 ER - TY - JOUR AU - Spoerke, J. M. AU - Gendreau, S. AU - Walter, K. AU - Qiu, J. AU - Wilson, T. R. AU - Savage, H. PY - 2016 DA - 2016// TI - Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant JO - Nat Commun. VL - 7 UR - https://doi.org/10.1038/ncomms11579 DO - 10.1038/ncomms11579 ID - Spoerke2016 ER - TY - JOUR AU - Sharma, G. AU - Mirza, S. AU - Parshad, R. AU - Gupta, S. D. AU - Ralhan, R. PY - 2012 DA - 2012// TI - DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients JO - Tumour Biol VL - 33 UR - https://doi.org/10.1007/s13277-012-0443-y DO - 10.1007/s13277-012-0443-y ID - Sharma2012 ER - TY - JOUR AU - Avraham, A. AU - Uhlmann, R. AU - Shperber, A. AU - Birnbaum, M. AU - Sandbank, J. AU - Sella, A. PY - 2012 DA - 2012// TI - Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients JO - Int J Cancer VL - 131 UR - https://doi.org/10.1002/ijc.27526 DO - 10.1002/ijc.27526 ID - Avraham2012 ER - TY - STD TI - Takahashi H, Kagara N, Tanei T, Naoi Y, Shimoda M, Shimomura A et al. Correlation of methylated circulating tumor DNA with response to neoadjuvant chemotherapy in breast cancer patients. Clin Breast Cancer. 2016. DOI:10.1016/j.clbc.2016.06.006. ID - ref76 ER -